C07K 16/11
Paramyxoviridae
Official title: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
C07K16/11 (Paramyxoviridae) appears on 363 US grants and 595 published applications in this corpus.
Search patents in C07K- Granted patents
- 363
- Published applications
- 595
- Assignees
- 243
- Inventors
- 901
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 0 | 0 |
| 1998 | 5 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 3 |
| 2002 | 2 | 10 |
| 2003 | 3 | 6 |
| 2004 | 4 | 17 |
| 2005 | 3 | 14 |
| 2006 | 3 | 12 |
| 2007 | 8 | 11 |
| 2008 | 5 | 6 |
| 2009 | 6 | 14 |
| 2010 | 10 | 24 |
| 2011 | 5 | 15 |
| 2012 | 9 | 25 |
| 2013 | 9 | 13 |
| 2014 | 11 | 28 |
| 2015 | 13 | 16 |
| 2016 | 19 | 53 |
| 2017 | 19 | 25 |
| 2018 | 31 | 30 |
| 2019 | 21 | 33 |
| 2020 | 25 | 44 |
| 2021 | 17 | 34 |
| 2022 | 23 | 27 |
| 2023 | 24 | 33 |
| 2024 | 21 | 45 |
| 2025 | 22 | 38 |
| 2026 | 24 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- RNA encoding an antibody29 Sep 2026US 12,747,451 B2Cure Vac SE
- Molecules with altered neonate Fc receptor binding having enhanced therapeutic and diagnostic properties25 Aug 2026US 12,715,933 B2MedImmune, LLC
- Methods of treatment of cancer with antibody-IL-2 engrafted proteins28 Jul 2026US 12,691,181 B2Novartis Institute for Functional Genomics, Inc.
- Betacoronavirus mRNA vaccines19 May 2026US 12,629,412 B2ModernaTX, Inc.
- Anti-respiratory syncytial virus antibodies, methods of their generation and use19 May 2026US 12,630,611 B2Mapp Biopharmaceutical, Inc.
- Compositions and methods for the treatment of immunodeficiency24 Sep 2026US 2026/0285950 A1Adma Biomanufacturing, LLC
- Genetic engneering of b cell receptors and uses thereof in antigen-induced antibody secretion17 Sep 2026US 2026/0274916 A1Ramot at Tel-Aviv University Ltd.
- Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof17 Sep 2026US 2026/0274995 A1ModeX Therapeutics, Inc.
- Anti-respiratory syncytial virus antibodies, methods of their generation and use3 Sep 2026US 2026/0258115 A1Mapp Biopharmaceutical, Inc.
- Anti-rsv monoclonal antibody formulation20 Aug 2026US 2026/0240992 A1MedImmune, LLC
Most cited
By later US patents
- Human-murine chimeric antibodies against respiratory syncytial virus163US 5,824,307 AMedImmune, LLC · 1998
- Antibody purification154US 5,429,746 ASmith Kline Beecham Corporation · 1995
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof110US 5,811,524 AIDEC Pharmaceuticals Corporation · 1998
- Methods for treating disease states comprising administration of low levels of antibodies97US 6,294,171 B2Milkhaus Laboratory, Inc. · 2001